Scholarlink

<p>Dimethylcurcumin (DMC) is a curcumin analogue that shows promising prospects in the treatment of androgen receptor-related diseases. However, DMC exhibits extremely poor water solubility and low bioavailability. In the present study, we synthesized dextran-polycaprolactone copolymers with different molecular weight of polycaprolactone for DMC delivery, namely Dextran-PCL4500 and Dextran-PCL7500. Dextran-PCL4500 and Dextran-PCL7500 can self-assemble into nanoparticles with low critical micellar concentration. DMC was loaded into Dextran-PCL4500 and Dextran-PCL7500 nanoparticles by ultrasonic emulsification-evaporation method. By optimization of the preparation process, DMC@Dextran-PCL4500 and DMC@Dextran-PCL7500 nanoparticles with moderate drug loading content were prepared. The DMC-loaded nanoparticles exhibit good colloidal stability and sustained drug release patterns. DMC@Dextran-PCL4500 exhibit enhanced cellular uptake as compared to DMC@Dextran-PCL7500 and free DMC. DMC@Dextran-PCL4500 and DMC@Dextran-PCL7500 show significant potential for cancer therapy.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Preparation and optimization of dextran-polycaprolactone nanoparticles with different molecular weight of polycaprolactone for effective dimethylcurcumin delivery

  • 期刊论文

  • 发表日期：

    2026年2月17日

查看全文
  • Shunze Gong,
  • Haotian Hu,
  • Xuanye Lu,
  • Yinxiu Jin,
  • Defeng Xu,
  • Hang Hu

摘要

Dimethylcurcumin (DMC) is a curcumin analogue that shows promising prospects in the treatment of androgen receptor-related diseases. However, DMC exhibits extremely poor water solubility and low bioavailability. In the present study, we synthesized dextran-polycaprolactone copolymers with different molecular weight of polycaprolactone for DMC delivery, namely Dextran-PCL4500 and Dextran-PCL7500. Dextran-PCL4500 and Dextran-PCL7500 can self-assemble into nanoparticles with low critical micellar concentration. DMC was loaded into Dextran-PCL4500 and Dextran-PCL7500 nanoparticles by ultrasonic emulsification-evaporation method. By optimization of the preparation process, DMC@Dextran-PCL4500 and DMC@Dextran-PCL7500 nanoparticles with moderate drug loading content were prepared. The DMC-loaded nanoparticles exhibit good colloidal stability and sustained drug release patterns. DMC@Dextran-PCL4500 exhibit enhanced cellular uptake as compared to DMC@Dextran-PCL7500 and free DMC. DMC@Dextran-PCL4500 and DMC@Dextran-PCL7500 show significant potential for cancer therapy.

Graphical abstract